1Bierhaus A , Hofmarm MA , Ziegler R , et al. AGE and their interaction with AGE-receptors in vascular disease and diabetesmellitus[J]. Cardiovasc Res , 1998 ,37 (3) :586- 600.
2Aksun AS,Ozmen B,Ozmen D, et al. Serum and urinary nitric oxide in Type 2 diabetes with or without microalbu- minutia: relation to glomerular hyperfiltration[J]. Diabe- tes Complications, 2003, 17 (6) : 343-348.
3Enomoto M, Adachi H, Yamagishi S, et al. Positive as sociation of serum levels of advanced glycation end products with thrombogenic markers in humans [J]. Metabolism, 2006, 55 (7): 912-917.
4ZIEMAN S .J, KASS D A. Advanced glycation end products cross21inking in the cardiovascular system potential therapeutic target for cardiovascular disease[J]. Drugs, 2004 ,64:459-470.
5KISHIKAWA H ,MINE S ,KAWAHARA C , et al. Glycated albumin and cross2 linking of CD44 induces scavenger receptor expression and uptake of oxidized LDI in human monocytes[J] . Biochem Biophys Res CommUN , 2006 ,339 (3) :846-851.
4Kahn SR. Frequency and determinants of the post thrombotic syndrome after venous thromboembolism [ J ]. Curr Opin Pulm Med, 2006,12 (5) : 299 - 303.
5Deatrick KB, Eliason JL, Lynch EM, et al. Vein wall remodeling after deep vein thrombosis invol'res matrix metalloproteinases and late fibrosis in a mouse Model[J]. J : ascsurg, 2005,42(5) :140 -148.
6Tahara N, Yamagishi S, Mttsui T, et al. Serum levels of advanced glyca- tion end products (AGEs) are independent correlates of insulin resistance in nondiabetic subjects [ J ]. Cardiovasc Ther, 2012,30 ( 1 ) :42 - 48.
7Ostendorp T, Leclere E, E alichet A, et al. Structural and functional in-sight into RAGE activation by multimeric S100B[ J]. EMBO J, 2007,26 (16) :3868 - 3878.
8Shbaklo H, Holcroft CA, Kahn SR. Levels of inflammatory markers and the development of the post thrombotic syndrome[J]. Thromb Haemost, 2009,101 (3) :505 - 512.
9Deane R, Singh I, Sagare AP, et al. A muhimodal RAGE - specific in- hibitor reduces amyloid beta - mediated brain disorder in a mouse model of Alzheimer disease [ J ]. J Clin Invest, 2012,122 (4) : 1377 - 1392.
